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INTRODUCTION 
 
Lymphopenia accompanies some autoimmune diseases
1
. A number of studies
2, 3
, but not 
others
4, 5
, have suggested that lymphopenia occurs in treatment-naive multiple sclerosis 
(MS), so the issue remains unresolved. This is important since lymphopenia may identify an 
immunologically distinct subset of MS. Also, lymphopenia may emerge as a risk factor for 
serious viral infections of the brain during dimethyl fumarate treatment
2
. We therefore 
embarked on a retrospective controlled study of pre-treatment lymphopenia in relapsing 
MS. 
 
METHODS 
 
Data was collected retrospectively during an institutionally-approved service evaluation of 
blood-test monitoring of patients with relapsing MS in a regional MS service in 
Southampton, UK over a two year period (2012-2014). MS diagnosis was by McDonald 
criteria. The following data was collected: age, sex, comorbidities, type of relapsing MS, date 
of first MS symptom onset, number of functional systems affected, pre-treatment and post-
treatment lymphocyte counts and their dates, relapse date and severity (three categories
6
), 
and date of treatment initiation. To calculate a relapsing disease severity index, mean 
relapse severity was multiplied by relapse rate. Control lymphocyte data was derived from 
pre-operative blood counts of age and sex-matched individuals undergoing septoplasty in 
the same hospital for structural reasons, excluding neoplastic and infective operative 
indications. Lymphopenia was classified according to CTCAE v4. Statistical analysis was 
conducted in SPSS v22. Null hypotheses were rejected at p<0.05. 
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RESULTS 
 
764 patients were identified with blood test data (Table 1). Baseline and post-treatment 
blood tests were available in 466 and 247 patients respectively. Average blood test 
frequency was 4/year. Lymphocyte counts were relatively stable with time, with a 
coefficient of variation of 7.5%. 
 
The mean lymphocyte count in treatment-naive MS patients was 2.18x10
9
/L with a standard 
deviation of 0.66x10
9
. Lymphopenia was present in 10% (47 patients; 46 Grade I, one Grade 
II, one Grade III). A detailed retrospective review of the medical records of all lymphopenic 
patients was undertaken to look for recognized causes of lymphopenia
1
. In only three cases 
steroids were administered in the month prior to lymphopenia; one case with borderline 
baseline lymphocytes developed a Grade III lymphopenia two days after steroids, while 
blood tests prior to steroids were unavailable in two cases with a Grade I lymphopenia.  
 
There was no association between pre-treatment lymphocyte count and any patient 
characteristic (age, sex, MS type, autoimmune comorbidities, age at onset of first MS 
symptom, disease duration, time since last relapse, number of functional systems affected, 
relapse rate, last relapse severity, and severity index) or month or season (using correlation 
coefficients, group comparison tests and linear or logistic regression). In the UK, during the 
study period, patients with higher disease activity (≥2 disabling relapses in 1 year) received 
natalizumab, and treatment options for lower disease activity included interferon-beta, 
glatiramer acetate and fingolimod. This binary treatment destination was used as a marker 
of disease activity. In a multivariate logistic regression, pre-treatment lymphocyte count or 
5 
 
lymphopenia did not predict natalizumab use, while younger age and higher relapsing 
disease severity index did (Odds ratios of 0.9 and 25 respectively, p<0.0001). 
 
We compared the lymphopenia observed in the pre-treatment MS population with an age 
and sex-matched control hospital population undergoing cosmetic septoplasty who had pre-
operative blood tests on the same haematology analyser. There was no statistical difference 
in mean lymphocyte count or prevalence of lymphopenia (Table 1). 
 
After treatment with interferon-beta or glatiramer acetate, the prevalence of sustained 
lymphopenia rose to 28% (26% Grade I, 2% Grade 2). Lymphocytes decreased after starting 
interferon-beta (mean decrease of 0.3x10
9
/L, p<0.0001, paired t-test), but not glatiramer 
acetate. Multiple logistic regression identified low pre-treatment lymphocyte count as the 
only predictor of post-treatment lymphopenia (Odds ratio of 0.1, p=0.001). 
 
Fingolimod caused a lymphopenia in all patients (range: 0.3-1.4x10
9
/L; median decrease of 
1.5x10
9
/L compared to baseline, p<10
-6
, Wilcoxon); using multiple linear regression, pre-
treatment lymphocyte count was the only predictor of post-treatment count (R
2
=0.22, B=0.1, 
p=0.003). Natalizumab increased lymphocyte count (median decrease of 1.3x10
9
/L 
compared to baseline, p<10
-14
, Wilcoxon; lymphocytosis >4x10
9
/L in 23% vs 0%). 
 
DISCUSSION 
 
Since the lymphocyte reference range covers 95% of values in a healthy population, 
lymphopenia is expected in 2.5%
1
. In our treatment-naïve relapsing MS population, we 
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found lymphopenia in 10%. However, this was not different from a well-matched healthy 
control population. Moreover, lymphopenia was not associated with relapsing activity. 
Hence the lymphopenia in MS patients is unlikely to be related to autoimmunity. A more 
likely explanation is stress-induced lymphopenia in both cohorts, through cortisol or EBV 
activation
7
.  
 
We found that pre-treatment lymphopenia predicts post-treatment lymphopenia; this is 
useful since it identifies at-risk patients needing frequent monitoring. Due to this study’s 
retrospective nature, lymphocyte subsets were not available, and these are important
4, 5
. 
Further work is needed to determine whether lymphocyte subsets during lymphopenia 
differ in MS patients versus controls. 
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Table 1 
Characteristic  Total MS population MS patients with baseline lymphocyte count Control population p 
      
N  764 466 102  
Age (mean ± SD, range) 
 
44 ± 10, 21-67 43 ± 9, 19-67 42 ± 14, 19-67 0.17a 
Sex (female, male, in %)  76, 24 73, 27 75, 25 0.71
b
 
Pretreatment lymphocyte count 
(mean ± SD, range, in x10-9/L) 
  
2.18 ± 0.66, 0.4-5.9 2.06 ± 0.56, 1-3.2 0.14a 
Prevalence of lymphopenia   10.1% 13.7% 0.29
b
 
Type of relapsing MS (RR, SP with 
relapses, PR, not recorded, in %)  73, 7, 1, 19 
   
Age at onset of MS 
(mean ± SD, range) 
 
32 ± 9, 14-66 
   
Disease duration 
(mean ± SD, range) 
 
10 ± 8, 0-43 
   
Relapse rate 
(mean ± SD, range)  0.68 ± 0.56, 0-6 
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EDSS* 
(mean ± SD, range) 
 
4.1 ± 2.3, 0-8 
   
Treatment 
(IFN, GA, FING, NAT, OTHER, 
in %)  49,25,10,15,1 
   
 
* Data only available in 18% of cases 
a
 Mann-Whitney 
b
 Fisher exact test  
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